BIO-TECHNE Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TECH in the last 30 days.
See all $TECH insider activity →Bio-Techne Corp's average stock price target increased from $70.9 to $73.22 by 9 analysts, with a range of $73 to $75. This suggests a 1% upside from the Oct. 1 closing price. The consensus rating remains 'Hold' among 13 analysts.
Bio-Techne (TECH) shareholders approved a $11.3B takeover by Merck KGaA at $73/share, but rejected the executive pay package. Shares closed at $72.57. The deal, subject to remaining approvals, is expected to close in late 2026 or early 2027.
BASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TECH (BIO-TECHNE Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TECH coverage spans mergers & acquisitions, corporate actions and earnings.
Modest upward pressure as the new target suggests slight upside.
The approval removes a major hurdle, making the deal likely to close in late‑2026/early‑2027.
Deal pricing largely reflected in current share price.
The acquisition approval removes a major uncertainty and sets the stage for a cash‑rich transaction that could lift the stock.
Deal approval likely lifts Bio-Techne stock and may trigger Merck-related moves.
AlphAI scores every news story that mentions TECH with an AI model for sentiment and relevance, and aggregates insider trades from BIO-TECHNE Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Techne Corp's average stock price target increased from $70.9 to $73.22 by 9 analysts, with a range of $73 to $75. This suggests a 1% upside from the Oct. 1 closing price. The consensus rating remains 'Hold' among 13 analysts.
1 min readBio-Techne (TECH) shareholders approved a $11.3B takeover by Merck KGaA at $73/share, but rejected the executive pay package. Shares closed at $72.57. The deal, subject to remaining approvals, is expected to close in late 2026 or early 2027.
2 min readBASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.
3 min readBIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany MINNEAPOLIS – September 23, 2026 – Bio-Techne Corporation (NASDAQ: TECH) (“Bio-Techne”), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne
2 min readBio-Techne (TECH) shareholders approved a merger with Merck KGaA. The deal, expected to close by early 2027, requires regulatory approvals. Bio-Techne reported $1.2B in net sales for fiscal 2025. The transaction aims to combine life sciences operations and deliver cash value to shareholders.
2 min readBio-Techne faces a shareholder lawsuit and demand letters challenging its proxy disclosures for the pending acquisition by Merck KGaA. The lawsuit seeks to halt the shareholder vote scheduled for September 23, 2026. Bio-Techne plans to supplement the proxy with additional disclosures on the sale process and financial advisor details, which may impact investor assessment of the deal.
2 min readBIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“ Bio-Techne ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Merck KGaA, Darmstadt, Germany, a German corporation with general par
2 min readBruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.
3 min readBio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
3 min readMerck KGaA has proposed to acquire Bio-Techne Corp. for an undisclosed amount. The deal, announced June 25, 2026, is expected to close by late 2026 or early 2027. Bio-Techne is a leader in proteins and immunoassays for academic, biopharmaceutical, and diagnostic markets.
1 min read
